James N. Topper Buys 1,135 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $21.76 on Friday. The firm has a market cap of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. The business’s 50 day simple moving average is $21.66 and its 200 day simple moving average is $21.20. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on NAMS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Needham & Company LLC reduced their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $43.33.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NAMS. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $50,000. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the fourth quarter worth $80,000. Quarry LP lifted its stake in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares during the last quarter. Finally, Barclays PLC grew its position in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.